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VERIFIABLE CPD PAPER
undergo well-characterised hierarchial 
self-assembly into three-dimensional 
fibrillar scaffolds in response to specific 
environmental triggers,4–6 offering a new 
generation of well-defined biopolymers 
with a range of potential applications.7 
At peptide concentrations used here, P11-4 
switches from a low viscosity isotropic 
liquid to an elastomeric nematic gel at 
pH <7.4 and in the presence of cations, 
conditions presumed to be found within a 
caries lesion.8 In a number of in vitro and 
in vivo experiments, the assembled P11-4 
INTRODUCTION
We previously described the effect of 
application of an anionic self-assembling 
peptide, P11-4, on the remineralisation and 
demineralisation behaviour of caries-
like lesions under simulated intra-oral 
conditions.1 Peptide treatment signifi-
cantly increased net mineral gain due to 
a combined effect of increased mineral 
gain and inhibition of mineral loss. In 
addition, P11-4 in its assembled form was 
shown to induce hydroxyapatite nuclea-
tion de novo. Based upon these data, we 
predicted that self-assembling peptides 
would be useful in the modulation of 
mineral behaviour during in situ dental 
tissue engineering.
P11-4 is a rationally-designed self-assem-
bling peptide.2,3 Self-assembling peptides 
Objective  We previously reported that a rationally designed biomimetic self-assembling peptide, P11-4, nucleated hy-
droxyapatite de novo and was apparently capable of in situ enamel regeneration following infiltration into caries-like 
lesions. Our present aim was to determine the safety and potential clinical efficacy of a single application of P11-4 on early 
enamel lesions. Materials and methods  Fifteen healthy adults with Class V ‘white spot’ lesions received a single applica-
tion of P11-4. Adverse events and lesion appearances were recorded over 180 days. Results  Patients treated with P11-4 
experienced a total of 11 adverse events during the study, of which two were possibly related to the protocol. Efficacy 
evaluation suggested that treatment with P11-4 significantly decreased lesion size (p = 0.02) after 30 days and shifted the 
apparent progression of the lesions from ‘arrested/progressing’ to ‘remineralising’ (p <0.001). A highly significant improve-
ment in the global impression of change was recorded at day 30 compared with baseline (p <0.001). Conclusions  The 
results suggest that treatment of early caries lesions with P11-4 is safe, and that a single application is associated with 
significant enamel regeneration, presumably by promoting mineral deposition within the subsurface tissue.
fibres were shown to be highly biocompat-
ible with low immunogenicity.9,10
Assembled P11-4 forms scaffold-like 
structures with negative charge domains, 
mirroring biological macromolecules in 
mineralised tissue extracellular matri-
ces (ECM).11 Proteins of the developing 
enamel ECM – themselves known to form 
self-assembling supramolecular struc-
tures12 – have long been thought to con-
trol initial mineral deposition (‘nucleation’) 
and subsequent crystal growth, ultimately 
determining the physico-mechanical 
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• Describes a rationally-designed peptide-
based biomaterial capable of infiltrating 
early caries lesions where it is thought 
to form scaffold-like structures via a 
process of self-directed assembly.
• Suggests that peptide scaffolds promote 
enamel regeneration in situ within the 
lesion, potentially providing a new 
therapeutic option that is minimally 
invasive and highly acceptable to 
patients.
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properties of the mature tissue.13 Mutations 
in enamel extracellular matrix proteins 
result in enamel defects in amelogenesis 
imperfecta, underlining the importance 
of protein-mineral interactions during 
enamel biomineralisation.14,15 Nucleation 
of mineral de novo is the first step in both 
the biomineralisation process and when 
designing biomaterials for mineralised tis-
sue regeneration. Dental enamel mineral 
is comprised of a substituted hydroxya-
patite, Ca10(PO4)6(OH)2 (Fig. 1a), with car-
bonate, fluoride and magnesium being the 
most common heteroionic substitutents.16 
Nucleators act to bring together constitu-
ent mineral ions from the surrounding 
disorganised ionic mileu within the tissue 
fluids into a highly ordered crystal lattice 
structure by stabilising critical nucleii to 
permit crystal growth. In order to control 
the deposition of hydroxyapatite crystals 
during biomineralisation, critical ionic 
nuclei need to be formed by collision 
of relevant ions. Such nuclei need to be 
stable before subsequent crystal growth 
(Fig.  1b). Proteins of the extracellular 
matrices of mineralised tissues, which can 
bind constituent ions and stabilise critical 
nuclei, thus reducing the activation energy 
required (‘heterogeneous nucleation’) are 
important in the biological control of 
biomineralisation.
In a biomimetic strategy based on reca-
pitulating normal enamel histogenesis, we 
proposed that following P11-4 self-assem-
bly, the anionic groups of the P11-4 side 
chains would attract Ca++ ions, inducing 
de novo precipitation of hydroxyapatite as 
indicated in our earlier study.1 
Enamel caries is a progressive subsur-
face demineralisation ultimately resulting 
in mechanical failure and cavitation.17 
Invasive surgical treatment for enamel 
restoration has changed little in the past 
decades, despite advances in dental mate-
rials themselves. The earliest clinical sign 
of enamel caries is the appearance of a 
‘white spot’ lesion on the tooth surface.18 
At this stage, clinicians frequently elect to 
monitor lesion appearance, perhaps after 
the use of topical fluorides, to determine 
whether or not the lesion will progress, in 
which case a restoration would then be 
placed. Non-surgical intervention promot-
ing defect biomineralisation or regenera-
tion at the white spot lesion stage would 
remove the need to ‘wait and see’ and 
avoid the ultimate excavation of the tooth 
to place a restoration.
We hypothesised that infiltration of 
early (‘white spot’) caries lesions using low 
viscosity monomeric P11-4 would result in 
triggered self-assembly within the lesion, 
generating a subsurface bioactive scaffold 
capable of recapitulating normal histogen-
esis by inducing mineral deposition in situ 
(Fig. 2).
The specific aim of the present study 
was to conduct a first-in-man clinical 
safety study applying a single treatment of 
P11-4 to Class V enamel lesions in healthy 
human volunteers.
MATERIALS AND METHODS 
Preparation of P11‑4
HPLC purified peptide P11-4 (CH3CO-
QQRFEWEFEQQ-CONH2) was acquired 
from PolyPeptide Group (France). Mass 
spectrometry found an experimental 
molecular weight of 1,595.8 (expected 
molecular weight = 1,595.7). Peptide con-
tent was determined by amino acid analy-
sis and UV absorbance and found to be 
89.2 ± 2.5% (expected maximum peptide 
content = 90.5%, calculated taking into 
account only bound counterions, not 
bound water).
Sub critical nucleus:
lons break apart
Critical nucleus:
Crystal growth
Fig. 1b  Diagram 
illustrating 
nucleation and 
crystal growth
Fig. 2  Schematic showing underlying hypothesis for treatment of early caries using P11‑4 self 
assembling peptides. (1) Early caries appears as a ‘white spot’ on the enamel surface (*), this is 
due to the underlying porosity in the tissue (2). Aqueous P11‑4 in its monomeric form applied to 
the lesion surface (3) will penetrate in to the pores due to its low viscosity (4). Self‑assembly 
is triggered by the conditions (pH <7.4, presence of salts) within the lesion forming fibres (5) 
which can nucleate hydroxyapatite mineral (6). This restores both the enamel mineral and the 
natural appearance (7) of the original lesion
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P11-4  was dissolved in water 
(18.2  MΩ-cm) at a concentration of 
6.3 mM. A solution of 1% ammonia was 
added drop wise until a pH of 8.6 ± 0.1 was 
achieved. The sample was then vortexed 
and sonicated to produce a clear colour-
less monomeric fluid. Aliquots (0.05 ml) 
of monomeric P11-4 were pipetted into 
individual vials, flash frozen with liquid 
nitrogen and lyophilised for 24 hours. The 
individual samples were then sealed with 
a crimp.
Selection of volunteers
Ethical approval was obtained through 
the UK National Research Ethics System 
(NRES; project number 10/H1207/75). 
Subjects were recruited from staff and 
patients attending Leeds Dental Institute 
(LDI). The study was conducted according 
to ISO 14155:2003  in the University of 
Leeds Translational and Clinical Research 
Unit at LDI. Fifteen subjects with 19 lesions 
were recruited according to the following 
criteria: included in the study were:
•	Subjects with ≥1 visible and accessible 
early caries lesion present, which did 
not require operative intervention
•	Subjects aged between 18 and 65 years 
who were willing and able to observe 
good oral hygiene and attend for the 
study visits
•	Subjects with more than 20 teeth 
present and a Basic Periodontal 
Examination (BPE) score of less than 
three
•	Subjects who were willing and able 
to understand all study-related 
procedures.
Excluded from the study were:
•	Subjects with >1 caries lesion present 
on the selected tooth
•	Subjects who had a significant medical 
history, including pregnancy and 
breast feeding or if they smoked more 
than five cigarettes per day
•	Subjects who had evidence of reduced 
salivary flow or significant tooth wear
•	Subjects who were participating in 
concurrent clinical trials or who had 
recently participated in other clinical 
trials of an investigational drug or 
device.
Mean subject age for the study group 
was 34.4 ± 12.7 years. The group com-
prised of seven females and eight males. 
Tooth type, lesion position and lesion 
activity are shown in Table 1.
Baseline assessment (Day 1)
The following baseline assessments were 
performed:
•	A general oral and physical 
examination including a dental, medical 
and social history and vital signs
•	A series of digital colour photographs 
of the test lesion taken under standard 
conditions of light and magnification
•	A detailed relevant medical (including 
dental) history covering the previous 
three years and any medication they 
were taking at the time of the study. 
At each recall the patients were ques-
tioned to determine whether or not they 
might have experienced any adverse 
events since their last visit and to identify 
any new medication(s) that they had taken 
since joining the trial.
Clinical procedures
The test lesion was cleaned with a proph-
ylaxis paste (Kemdent Flour of Pumice, 
ADP Ltd, Swindon, UK) and isolated. The 
lesion was then treated with etch solution 
(Super Etch, SDI Ltd, Bayswater, Victoria, 
Australia) for 30 seconds to open up the 
pores to the subsurface lesion and sub-
sequently washed and dried. Lyophilised 
P11-4 was rehydrated with 0.05 ml of ster-
ile water and a single drop of the result-
ing solution immediately applied directly 
to the lesion surface. Moisture control was 
ensured until the P11-4 solution was no 
longer visible (approximately two minutes).
Subjects were advised not to brush the 
quadrant containing the treated tooth 
until Day 4 (D4) review visit. Instead, sub-
jects were asked to rinse that area of the 
mouth with a chlorhexidine mouthwash 
(Corsodyl, GSK, Herrenberg, Germany). At 
D4, a soft toothbrush and toothpaste were 
provided and subjects asked to use these 
until Day 8 (D8) review visit. At this point 
they reverted to their normal oral hygiene 
procedures.
Review assessments  
(D4, D8, D30 and D180)
Subjects were reviewed at 4, 8, 30 and 
180 days after treatment. At each visit the 
following assessments were conducted:
•	Visual inspection of the treated site 
was carried out and any potential 
adverse events recorded
•	Vital signs were recorded
Table 1  Tooth type, lesion position and lesion activity at baseline for teeth treated with 
P11‑4
Patient-number Tooth number and lesion position* Lesion activity at baseline as judged by VAS**
1-001 36b -0.5
1-002 46b 20.5
1-003 46b 11
1-004 46b -11
1-005 46b -5.5
1-006 46b -3.5
1-007 46b 6
1-008 46b -2.5
1-009 16b 1.5
1-010 16l 15
1-011 44b 7
1-012 35b 3.5
1-013 43b 9.5
1-014 14b 9.5
1-015 24b -16.5
*b = buccal; l = lingual
**VAS scale from -50 to +50; negative numbers represent a remineralising lesion; positive numbers present an active lesion. Arrested 
lesions score ‘0’.
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•	A series of colour photographs of the 
test lesion were taken under standard 
conditions of light and magnification
•	At D30 and D180, a Global Impression 
of Change questionnaire was 
completed by both the subjects and 
dental professionals.
Assessment of lesion appearance 
and progression
Colour photographs of all lesions from all 
subjects were used to assess lesion size, 
appearance and progression. Blind assess-
ment was carried out independently by 
two experienced clinicians using a global 
impression of change questionnaire and a 
visual analogue scale (VAS).
Interim assessment was carried out by 
comparing lesion size and appearance at 
D4, D8 and D30 to D1 (baseline). Final 
assessment was carried out by comparing 
D180 with D30 and correlating the data to 
the interim assessment. 
Colour photographs for all assessments 
were selected by a member of staff who was 
not involved in the study and were each 
allocated a unique identifier including the 
day of the visit in order that comparisons 
with baseline might be made. As such, the 
assessors would not have been blind to 
the identity of the lesions at baseline. To 
address this, D1 and D30 photographs were 
‘switched’ according to a randomisation 
table such that the assessors did not know 
whether they were making comparisons 
against ‘true’ D1 baseline. Neither assessor 
was aware which baseline data had been 
‘switched’. Where ‘switching’ had occurred, a 
real improvement with time after treatment 
would appear as an apparent deterioration.
Unblinding was performed after comple-
tion of all assessments and database lock.
Image analysis
For each lesion, digital images were selected 
from photographs taken at baseline (D1), 
D30 and D180. Lesion contour was marked 
by a blinded operator and the total number 
of pixels within contour boundaries deter-
mined using image analysis (Soft Imaging 
System, Münster, Germany). Only those 
images where tooth orientation was con-
sistent across the three visits were used 
(validated using tooth landmarks and a 
series of interconnecting lines) and hence 
a total of 12 (D1 & D30) and 11 (D180) 
lesions were analysed.
Statistical analysis
Data was analysed by an independent stat-
istician at the University of York.
Independent sample t-tests were used 
to determine any statistically significant 
differences between the two  assessors’ 
ratings for colour, size, progression and 
global impression of change.
A repeated measures t-test was used 
to assess statistically significant changes 
over time in the colour, size, progression 
assessments and the global impression of 
change. Fisher’s method was used to com-
bine p-values from the repeated measures 
t-tests for the two assessors, producing 
chi-squared test statistics that can be eval-
uated for statistical significance against 
2k degrees of freedom for k number of tests. 
The alpha value was adjusted to compen-
sate for positively associated tests (that is, 
lack of independence) using a(k + 1)/(2k), 
providing an alpha value of 0.0375.
RESULTS
All subjects completed all stages of the 
study with the exception of one  indi-
vidual who was lost to follow-up at 
D180 due to their relocation outside of 
the area. There were 11 recorded adverse 
events (See Table 2) of which two were 
judged by the investigator as probably 
related to the protocol used in the trial. 
One was a transient dental hypersensitiv-
ity; the other a sensitivity to the Corsodyl 
mouthwash provided within the study. 
All other adverse events were judged to 
Table 2  Recorded adverse events
Patient number Adverse event Treatment causality
1-002 Chest infection Not related
1-003 Dental hypersensitivity Possibly related
1-003 Sprained joint between spine and pelvis Not related
1-004 Stomach upset Not related
1-005 Sensitivity with corsodyl mouthrinse Possibly related
1-006 Diarrhoea and vomiting Not related
1-007 Superficial staining Not related
1-012 Chest infection Not related
1-013 Dental treatment Not related
1-015 Operation on Dupuytren’s Contraction Not related
1-015 Routine dental treatment Not related
Fig. 3  Examples of clinical appearance of two Class V caries lesions (arrows) in different 
subjects included in the study. Images selected to show the range of response to a single 
application of P11‑4 with time. (a, d) Lesion appearance at baseline (D0); (b, e) and (c, f) 
appearance of same lesion at D30 and D180 respectively
a
d
b
e
c
f
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be not related to the study. None of the 
adverse events were classified as serious.
The effect of treating the lesions using 
P11-4 was initially assessed based upon 
their clinical appearance using clinical 
photographs (Fig. 3). Statistical analysis 
of the scoring by the two assessors showed 
no significant differences in their assess-
ments across all of the measured outcomes.
The results of the clinicians’ global 
impression of change questionnaire are 
shown in Figure 4. Compared with base-
line, there was a significant improvement 
in the assessment scores 30 days after a 
single application of P11-4 (p  <0.001). 
This improvement was maintained even 
after 180  days post-treatment; results 
compared with baseline showed a highly 
significant improvement in the global 
impression of change scores (p <0.0001). 
No statistically significant differences in 
the global impression of change scores 
were seen when D180 was compared with 
D30, suggesting that the major treat-
ment effect for P11-4  had occurred by 
D30 post-treatment.
A VAS was used to assess specific lesion 
parameters including colour, size and pro-
gression based upon the appearance of the 
lesion in the clinical photographs.
Figure 5 summarises the VAS data for 
each of the follow up visits compared with. 
baseline. No significant differences were 
seen in any of the three parameters in the 
first follow up visit (D4). By D8, there was 
a significant difference observed in lesion 
colour (p <0.05) but this was not significant 
at any of the later time points, mainly due 
to the very large variation in the scoring. 
For lesion size and progression, there was 
an increasing trend towards improvement 
over the first eight days after treatment 
but this was not statistically significant 
until D30, where lesion size was judged 
to have significantly decreased (p <0.05) 
and lesion progression was judged to have 
moved from arrested/progressing to rem-
ineralising (p <0.01). This improvement 
in lesion size and progression was main-
tained at D180 (almost six months after 
the single application of P11-4).
Finally, in agreement with the clinical 
assessment, morphometic analysis also 
showed a significant decrease in lesion size 
compared with baseline at D30 (31 ± 24%, 
n = 11; p = 0.002) and D180 (40 ± 27%, 
n = 11; p = 0.001).
DISCUSSION
This small study represents a first-in-man 
clinical safety trial of a regenerative car-
ies therapeutic that has been rationally 
designed to recapitulate the processes 
occurring during enamel biominerali-
sation, where a self-assembled organic 
matrix controls the deposition and growth 
of hydroxyapatite crystals.13 As a potential 
treatment for early caries lesions, P11-4 is 
safe, non-invasive and acceptable to 
patients (as evidenced by the unanimous 
and significantly positive response on 
the patients’ global impression of change 
questionnaire [p = 0.0003]). However, it is 
important to note that this is not an effi-
cacy trial and as such we cannot compare 
the data obtained here with a ‘do nothing’ 
control or any other intervention, such as 
the application of topical fluoride.
We have previously shown that P11-4 is 
able to nucleate hydroxyapatite de novo 
and is able to promote repair of caries-
like lesions in vitro.1 The treatment differs 
from other ‘filling without drilling’ infil-
trative strategies in that P11-4  is a bio-
active peptide synthesised from natural 
amino acids that is triggered to assemble 
into a three dimensional fibrillar scaffold 
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Fig. 4  Results showing responses to global impression of change questionnaire of the effect of 
a single application of P11‑4 on the general appearance of the treated caries lesion
Fig 5.  Effect of a single application of P11‑4 on colour, size and progression of the treated caries 
lesion compared to baseline (D0) as judged by blinded assessors using a visual analogue scale 
from ‑100 to +100. Histograms show change in lesion colour (red); change in lesion size (yellow) 
and change in lesion progression (blue). Lesion colour: positive values indicate an improvement in 
lesion colour (ie less white). Lesion size: positive values indicate a lesion that is increasing in size; 
negative values a decrease in lesion size. Lesion progression: positive values indicate a lesion that 
is judged to be progressing, negative values indicate a lesion that is judged to be remineralising. 
Significance when compared with baseline indicated by *(p ≤0.05); **(p ≤0.001)
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by environmental conditions of pH and 
salt concentration. Assembly takes place 
within the lesion, and the scaffold can 
then act as nucleator for hydroxyapatite, 
effecting tissue regeneration from within. 
Infiltration of lesion pores using low vis-
cosity resins such as sealants has been 
demonstrated to halt caries progression 
in vitro,19,20 in situ21 and in vivo,22 presum-
ably by providing a barrier to diffusion 
within the lesion. The use of a biomimetic 
peptide such as P11-4 has the additional 
advantage of effecting ‘natural’ repair by 
regenerating the mineral itself. 
We used a global impression of change 
questionnaire coupled with assessment 
of clinical photographs using VAS and 
morphometric analysis of lesion size to 
determine any clinical benefit following 
treatment of the lesions with P11-4. Visual 
analogue scales are commonly used in 
dental research, for example in judging 
severity of fluorosis.23 We chose not to 
use radiographs as an outcome measure 
as the changes we were seeking to iden-
tify are relatively small, given that these 
are early lesions which do not themselves 
necessarily show on radiographs. We chose 
not to use caries detection devices as those 
currently available depend on surrogate 
indicators of lesion progression/detection 
(eg QLF depends on the enamel structure; 
Diagnodent depends on presence of por-
phyrins; CarieScan depends on conductiv-
ity or water) though it would be interesting 
to utilise these diagnostics in future effi-
cacy trials. The results of the study indicate 
that the clinical use of P11-4 is safe and, 
based upon clinical judgement, Class V 
lesions treated with a single application 
of P11-4 show significant improvement 
in their clinical appearance by D30. This 
improvement in size and progression was 
maintained even after 180 days post-treat-
ment and was further supported by the 
morphometric analysis. We do not know 
the kinetics of peptide-induced reminer-
alisation but the data suggests a safe and 
positive trend beginning at the earliest days 
post-treatment. It is also possible that the 
potential for lesion repair might be influ-
enced by the initial state of the lesion itself. 
We have no historical data relating to those 
lesions that were treated here and the small 
sample size means that we cannot make 
any evaluation as to whether initial lesion 
activity is related to treatment outcome. 
This would need to be addressed as part of 
a more comprehensive efficacy trial.
Despite the fact that this study was a 
small, non-controlled safety clinical trial, 
all of the outcome measures used showed 
beneficial results in respect of enamel 
regeneration. The results are therefore 
promising given that we have not yet 
investigated the optimum clinical delivery 
for P11-4 or the formulation of P11-4 itself. 
It may be that we can improve efficacy 
by pre-treating lesions to remove extra-
neous material, such as proteins that may 
be present within.24 In addition, we have 
yet to determine whether repeated applica-
tion of P11-4 would provide further enamel 
benefit for those lesions where repair was 
incomplete. Given that P11-4  is a well-
tolerated treatment, repeated application 
is an obvious way forward. Finally, we 
are currently designing and bench testing 
‘next generation’ peptides to accelerate 
the repair process, making ‘filling without 
drilling’ a reality.
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